VEGETARIAN CAPSULES FOR PHARMACEUTICAL APPLICATIONS

Capsugel®

LONZC Pharma & Biotech

Copsule Portfolio

Made better. By science.™

WHAT IS HPMC?

BENEFITS OF HPMC CAPSULES

- Excellent mechanical stability, even at low humidity/moisture conditions

- Low water content
- Global acceptance
- Non-animal origin
- No incidence of cross-linking
- High moisture tolerability range

HPMC (HydroxyPropyIMethyICellulose), or Hypromellose, is derived from wood pulp and consists of partly methylated and hydroxypropylated cellulose units.

HPMC is a cellulose-based structure as opposed to the amino acid-based structure of gelatin.

WHY CHOOSE HPMC CAPSULES?

Formulation Benefits	Some molecules create formulation issues requiring another material besides gelatin. HPMC capsules were introduced to alleviate the problems with APIs and excipients not compatible with gelatin as well as issues with moisture sensitivity and hygroscopicity. To achieve optimal formulation performance, it is important to understand the properties of HPMC capsules.
Stability Enhancement	HPMC capsules do not experience cross-linking. The larger moisture tolerability range of HPMC enables more stable formulations.
The Non-Animal Alternative	The non-animal origin of HPMC capsules eliminates BSE/TSE concerns and may avoid the need for typical import certifications associated with animal origin products. In addition, they are suitable for certain consumer preferences, such as those with a vegetarian lifestyle or religious requirements.
Our Offer	Lonza's Capsugel® HPMC capsule portfolio offers a wide variety of products to meet specific formulation and capsule performance needs. Our experts can work with you to adapt your formulation to a compatible Capsugel® vegetarian capsule.

LONZA'S CAPSUGEL® PHARMACEUTICAL HPMC CAPSULE PORTFOLIO



VCAPS[®] PLUS

Vcaps® Plus are an immediate-release capsule in HPMC only, without gelling agents. They offer an excellent dissolution profile with pH independent performance, low moisture content, great machinability and visual quality. Vcaps® Plus have an in-vivo performance bioequivalent to gelatin. They are also well suited for dry-powder inhalation applications.



VCAPS[®] ENTERIC

Vcaps[®] Enteric is a capsule technology that simplifies drug enteric delivery implementation. It offers an enteric-release profile to the upper GI tract that meets the disintegration requirements for delayed-release capsules from the European, US and Japanese Pharmacopoeia.



VCAPS®

Vcaps[®] capsules' gelling agent formulation offers stable and robust performance. They are suitable for moisture-sensitive product fills. As a traditional formulation with gelling agents, its dissolution profile is ideally suited for dry-powder inhalation applications.

ASK ABOUT OTHER CAPSUGEL® ALTERNATIVE POLYMER CAPSULES

PLANTCAPS®

Made from pullulan, these immediate-release capsules are ideal for oxygen-sensitive ingredients.

DRCAPS®

An innovative HPMC formulation that helps protect acid-sensitive ingredients. The low moisture level of DRcaps[®] provides enhanced stability for hygroscopic ingredients.

Lonza's Capsugel[®] HPMC Pharmaceutical Capsule Portfolio Certifications Preservative Free – Allergen Free – Starch Free













* Transparent and colored empty capsules are vegan certified. Empty capsules containing the colorant carmine are not vegan certified.

HPMC CAPSULE SELECTION GUIDE

The tables below are provided to help identify which Capsugel® HPMC capsule is best for your formulation. Our team of experts can help you determine the ideal customized solution to bring your product to market.

	Color options available	Print options available	Visual appearance	Current size range
Vcaps® Plus	Yes	Yes	Lustrous sheen similar to gelatin	00el to 4
Vcaps® Enteric	Contact us	Contact us	Off-white opaque	0 - 00
Vcaps®	Yes	Yes	Natural look with low gloss	000 to 4

	Applications	Moisture content	Intended use
Vcaps® Plus	Moisture-sensitive ingredients	Less than 9%, can be customized	Immediate release with in-vivo performance bioequivalent to gelatin — Dry-powder inhalation
Vcaps® Enteric	Enteric delivery	Less than 7%	Delayed release
Vcaps®	Hygroscopic and moisture-sensitive drugs	Less than 9%, can be customized	Dry-powder inhalation



The statements made in these materials have not been evaluated by the U.S. Food and Drug Administration or any other regulatory authority. Lonza's products are not intended for use to diagnose, treat, cure or prevent any disease. All product information corresponds to Lonza's knowledge on the subject at the date of publication, but Lonza makes no warranty as to its accuracy or completeness and Lonza assumes no obligation to update it. Product information is intended for use by recipients experienced and knowledgeable in the field, who are capable of and responsible for independently determining the suitability of the finished dosage form for intended uses and to ensure their compliance with applicable law. Proper use of this information is the sole responsibility of the recipient. It may not be applicable, complete or suitable for the recipient's finished product or application; therefore, republication of such information or related statements is prohibited. Information provided by Lonza is not intended and should not be construed as a license to operate under or a recommendation to infringe any patent or other intellectual property right. No claims are made herein for any specific intermediate or end-use application. All trademarks belong to Lonza or its affiliates or to their respective third parties and are used here only for informational purposes. © 2019 Lonza

CONTACTS



For further information about the products: Visit: www.capsugel.com EMEA: solutions.emea@lonza.com / +33 389 205725 AMER: solutions@lonza.com / 800 845 6973 Or contact your Lonza representative

CDS201909002-D